BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38688599)

  • 21. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
    Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
    BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
    Wu YS; Shui L; Shen D; Chen X
    Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose (7.5 mg/kg) bevacizumab may be a viable option in recurrent ovarian cancer: A retrospective study.
    Demirkiran A; Eryilmaz MK; Karaagac M; Araz M; Korkmaz M; Koçak MZ; Artac M
    J Cancer Res Ther; 2023; 19(3):595-600. PubMed ID: 37470581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
    Garcia Garcia Y; de Juan Ferré A; Mendiola C; Barretina-Ginesta MP; Gaba Garcia L; Santaballa Bertrán A; Bover Barcelo I; Gil-Martin M; Manzano A; Rubio Pérez MJ; Romeo Marin M; Arqueros Núñez C; García-Martínez E; Gonzalez Martin A
    Int J Gynecol Cancer; 2019 Jul; 29(6):1050-1056. PubMed ID: 31263024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
    Gore M; Hackshaw A; Brady WE; Penson RT; Zaino R; McCluggage WG; Ganesan R; Wilkinson N; Perren T; Montes A; Summers J; Lord R; Dark G; Rustin G; Mackean M; Reed N; Kehoe S; Frumovitz M; Christensen H; Feeney A; Ledermann J; Gershenson DM
    Gynecol Oncol; 2019 Jun; 153(3):541-548. PubMed ID: 31005287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.
    Chen WC; Qiu JT; Lai CH; Huang HJ; Lin CT; Chen MY; Chou HH; Huang KG; Chang TC
    PLoS One; 2017; 12(5):e0175703. PubMed ID: 28467466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
    Backes FJ; Richardson DL; McCann GA; Smith B; Salani R; Eisenhauer EL; Fowler JM; Copeland LJ; Cohn DE; O'Malley DM
    Int J Gynecol Cancer; 2013 Jun; 23(5):833-8. PubMed ID: 23640292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
    Liu JF; Herold C; Gray KP; Penson RT; Horowitz N; Konstantinopoulos PA; Castro CM; Hill SJ; Curtis J; Luo W; Matulonis UA; Cannistra SA; Dizon DS
    JAMA Oncol; 2019 Dec; 5(12):1731-1738. PubMed ID: 31600397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
    Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
    Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
    Li Y; Yang Y; Shang YM; Zheng H
    Indian J Cancer; 2014 Mar; 51 Suppl 3():e92-4. PubMed ID: 25818742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
    Zhang L; Chen Y; Li F; Bao L; Liu W
    Front Immunol; 2019; 10():867. PubMed ID: 31105696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of recurrent ovarian cancer.
    Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
    Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
    Verschraegen CF; Czok S; Muller CY; Boyd L; Lee SJ; Rutledge T; Blank S; Pothuri B; Eberhardt S; Muggia F
    Ann Oncol; 2012 Dec; 23(12):3104-3110. PubMed ID: 22851407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.
    Farolfi A; Scarpi E; Greco F; Bergamini A; Longo L; Pignata S; Casanova C; Cormio G; Bologna A; Orditura M; Zavallone L; Attademo L; Gallà V; Franzese E; Pigozzi E; Loizzi V; Giorda G; Giardina D; Cioffi R; De Giorgi U
    Sci Rep; 2020 Oct; 10(1):18190. PubMed ID: 33097745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
    Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
    Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report.
    Tarumi Y; Mori T; Matsushima H; Kokabu T; Tsuchiya H; Kitawaki J
    J Obstet Gynaecol Res; 2018 Feb; 44(2):347-351. PubMed ID: 29121427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?
    McCann GA; Smith B; Backes FJ; Rath K; Chacko S; Salani R; Eisenhauer E; Fowler JM; Cohn DE; O'Malley DM
    Gynecol Oncol; 2012 Nov; 127(2):362-6. PubMed ID: 22885866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.
    Hansen MKG; Smerdel MP; Waldstrøm M; Andersen RF; Adimi P; Jakobsen A; Steffensen KD
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):751-759. PubMed ID: 33067703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.